Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2
- PMID: 23086772
- DOI: 10.1309/AJCP05TTWQTWNLTN
Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2
Abstract
Sox2 amplification was recently reported as a common event in squamous cell carcinomas (SCCs) occurring at different anatomic sites including the lung. The objective of the study was to determine morphologic and clinicopathologic characteristics of lung SCCs with respect to Sox2 protein expression and gene amplification. One hundred forty-seven surgically treated non-small cell lung carcinomas were analyzed for Sox2 gene amplification by using fluorescence in situ hybridization and protein expression using immunohistochemical analysis. SCC showed more frequent Sox2 protein expression (52/66; 79%) than adenocarcinomas (ADC) (14/76; 18%) (P < .0001). Similarly, Sox2 amplification was more frequent in SCCs (52/70; 72%) than in ADCs (6/77; 8%) (P < .0001). Sox2 protein expression was associated with better overall survival in SCC (66 vs 14 months; P =.048). SCC with basaloid differentiation and severe nuclear atypia exhibited more intense Sox2 protein expression than other tumors. Sox2 appears to be an important gene in lung squamous cell carcinogenesis that in particular drives the development of poorly differentiated tumors.
Similar articles
-
SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.Hum Pathol. 2011 Aug;42(8):1078-88. doi: 10.1016/j.humpath.2010.11.010. Epub 2011 Feb 21. Hum Pathol. 2011. PMID: 21334718
-
Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.Oncol Rep. 2011 Oct;26(4):877-85. doi: 10.3892/or.2011.1349. Epub 2011 Jun 15. Oncol Rep. 2011. PMID: 21687954
-
Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.Am J Clin Pathol. 2006 Jun;125(6):860-5. doi: 10.1309/H5UW-6CPC-WWC9-2241. Am J Clin Pathol. 2006. PMID: 16690485
-
[Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].Rinsho Byori. 1996 Jan;44(1):32-41. Rinsho Byori. 1996. PMID: 8691638 Review. Japanese.
-
Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.Oncotarget. 2016 Jun 7;7(23):34520-31. doi: 10.18632/oncotarget.9145. Oncotarget. 2016. PMID: 27150062 Free PMC article. Review.
Cited by
-
SOX2 in cancer stemness: tumor malignancy and therapeutic potentials.J Mol Cell Biol. 2020 Feb 20;12(2):85-98. doi: 10.1093/jmcb/mjy080. J Mol Cell Biol. 2020. PMID: 30517668 Free PMC article.
-
SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin.Cancer Cell. 2016 Oct 10;30(4):519-532. doi: 10.1016/j.ccell.2016.09.001. Cancer Cell. 2016. PMID: 27728803 Free PMC article.
-
Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.BMC Cancer. 2016 Jan 19;16:28. doi: 10.1186/s12885-016-2061-3. BMC Cancer. 2016. PMID: 26780934 Free PMC article.
-
Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture.Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11671-E11680. doi: 10.1073/pnas.1803718115. Epub 2018 Nov 28. Proc Natl Acad Sci U S A. 2018. PMID: 30487219 Free PMC article.
-
An analysis of the influencing factors of false negative autoantibodies in patients with non-small cell lung cancer.Front Oncol. 2024 May 10;14:1358387. doi: 10.3389/fonc.2024.1358387. eCollection 2024. Front Oncol. 2024. PMID: 38800369 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
